Nasopharyngeal Carcinoma Prevention
Nasopharyngeal Carcinoma Prevention
Nasopharyngeal carcinoma cannot be prevented by diet or vaccination, but it can be found early. Plasma EBV DNA testing and endoscopy do that in high-risk groups, and early disease is among the most treatable cancers there is.
Why this cancer is worth screening for
Screening usually has to justify itself, and in nasopharyngeal carcinoma the argument is unusually clear. The disease begins in a place that produces no symptoms until it is advanced, it is common in a defined population, it has a measurable blood marker, and treatment in the early stages is highly effective. Those four conditions are exactly what a screening programme needs.
Against that sits the cost of investigating people who turn out not to have the disease, and the anxiety that comes with a false positive — which for a blood test in an endemic population is not negligible. That is why screening is targeted rather than universal. It is offered to people whose risk is high enough that the balance tips: those who grew up in or have close family from an endemic region, and those with a family history of the disease. Screening everyone else would generate far more investigation than diagnosis.
Plasma EBV DNA as a screening test
The screening test is a measurement of Epstein-Barr virus DNA in plasma. Because the tumour sheds viral DNA into the blood, the test can be positive before any symptom appears, and in prospective studies in endemic regions it has detected the disease at earlier stages than symptom-driven diagnosis does.
What a positive result means needs stating carefully, because it is not a diagnosis. A raised EBV DNA level means the test has flagged you as needing an examination of the nasopharynx — it does not confirm cancer, and it can be raised for other reasons. The confirmatory step is nasopharyngoscopy with biopsy, which is quick and definitive. Because the virus is carried by most adults, a single positive result in a low-risk person is more likely to be a false positive than a cancer; in a high-risk person the balance shifts. That difference in pre-test probability is the whole reason screening is restricted to high-risk groups.
Who should be screened, and how often
Screening is not for everyone, and the criteria are worth stating explicitly:
- Grew up in, or have close family from, an endemic region — southern China, Southeast Asia and North Africa. The relevant exposure is childhood, so where you grew up matters more than where you live now.
- A first-degree relative with nasopharyngeal carcinoma — the single strongest piece of family information, and the strongest reason to be tested.
- Persistent or recurring symptoms — a unilateral middle-ear effusion in an adult, blood-stained nasal discharge, or an unexplained upper neck lump. These are not screening indications but diagnostic ones, and they should not wait for a screening cycle.
- Interval — there is no single established interval, and practice varies between annual and every few years in screening programmes. The interval should be set by your risk and written down, rather than decided afresh at each visit.
If a relative has had the disease
A family history changes the practical advice in two ways. The first is that the threshold for testing drops: where a screening programme might test every year or two, someone with an affected first-degree relative is a candidate for regular testing from an earlier point, and both the EBV DNA test and endoscopy are reasonable. The second is that relatives should be told what to look for — an upper neck lump that persists, an ear that will not clear, blood-stained nasal discharge — so that a symptom leads to an examination rather than to a course of antibiotics.
What a family history does not justify is prophylactic treatment or surgery. There is no equivalent of the prophylactic thyroidectomy offered to RET carriers, because the disease has no single causative mutation to test for and no pre-malignant lesion that can be removed in advance. Screening and vigilance are the available tools, and they are effective ones, because the disease is highly treatable when it is found early.
Diet, and what is not worth doing
Dietary prevention is limited, and honesty about that is more useful than a list of foods to avoid. The established dietary factor is childhood consumption of Cantonese-style salted fish, and that exposure is historical — there is no dietary change in adulthood that reverses it. Beyond that, a diet high in fruit and vegetables and low in preserved foods is reasonable general advice, but there is no evidence that any specific change reduces the risk of this particular cancer.
Two things are worth avoiding for other reasons. Smoking raises the risk of the keratinizing type of nasopharyngeal carcinoma and of other head and neck cancers, and should be stopped on that basis. And in treated patients, dental disease and dry mouth interact badly with the after-effects of radiotherapy, so dental care is genuinely preventive — of a different problem, but a real one. Supplements, cleanses and folk remedies offer nothing here.
What screening cannot do
Three limits are worth stating plainly, because over-reading a screening test causes harm in both directions:
First, a negative EBV DNA test is not a guarantee. It reflects the amount of tumour present at the moment of sampling, and an early or small tumour may not shed enough viral DNA to be detected. A negative result does not justify ignoring a persistent neck lump. Second, a positive test is not a diagnosis, and most positive results in a single test are not cancer — which is why the confirmatory step is endoscopy rather than treatment. Third, screening has not been shown to reduce mortality in a randomised trial; the evidence comes from prospective cohort studies in endemic regions showing earlier stage at diagnosis, which is a strong but not identical claim.
A plan you can act on
Stripped of general advice, an actionable plan has four items:
- No risk factors and no symptoms — nothing to do. Screening is not indicated and would generate more false alarms than diagnoses.
- From an endemic region, or close family from one — ask about plasma EBV DNA testing with a stated interval, and have the nasopharynx examined at least once as a baseline.
- A first-degree relative with the disease — screen earlier and more often, and make sure the family knows which symptoms warrant an examination rather than a waiting period.
- Any persistent symptom — a neck lump, a blocked ear, blood-stained discharge in an adult — this is a diagnostic pathway, not a screening one, and it should be completed now rather than at the next cycle.
Our team can arrange EBV DNA testing and nasopharyngoscopy, and can review an endoscopy report and MRI from elsewhere. The written assessment states whether screening or diagnosis is the right pathway, and on what interval — returned within 48 hours of the file being complete.